WO2025134068 - ANTIBODY DRUG CONJUGATES TARGETING PROTEINOPATHIES, AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/134068
Publication Date
26.06.2025
International Application No.
PCT/IB2024/063062
International Filing Date
20.12.2024
Title **
[English]
ANTIBODY DRUG CONJUGATES TARGETING PROTEINOPATHIES, AND USES THEREOF
[French]
CONJUGUÉS ANTICORPS-MÉDICAMENT CIBLANT DES PROTÉINOPATHIES, ET LEURS UTILISATIONS
Applicants **
AC IMMUNE SA
Inventors
NAMPALLY, Sreenivasachary
MARTIN, Camille
KOSCO-VILBOIS, Marie
ADOLFSSON, Oskar
PFEIFER, Andrea
Priority Data
63/614,396
22.12.2023
US
63/675,382
25.07.2024
US
63/675,384
25.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6897 | |
| EPO | Filing, Examination, Granting | 143891 | |
| Japan | Filing, Examination, Granting | 5032 | |
| South Korea | Filing, Examination, Granting | 9521 | |
| USA | Filing, Examination, Granting | 36890 |
Total:
202,231
Contact Us
Abstract[English]
The invention provides antibody conjugate compositions comprising an antibody targeting a pathological protein covalently attached to one or more brain penetrant, pathological protein binding small molecule entities by a linker. The invention further provides methods of treating neurodegenerative diseases and disorders such as Alzheimer's disease with the antibody conjugate compositions.[French]
L'invention concerne des compositions de conjugués d'anticorps comprenant un anticorps ciblant une protéine pathologique liée de manière covalente à une ou plusieurs entités de petites molécules pénétrant dans le cerveau et se liant à des protéines pathologiques, par l'intermédiaire d'un lieur. L'invention concerne en outre des méthodes de traitement de maladies et de troubles neurodégénératifs, comme la maladie d'Alzheimer, avec les compositions de conjugués d'anticorps.